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OBJECTIVE— To examine the effects of acute insulin-induced hypoglycemia on inflamma-
tion, endothelial dysfunction, and platelet activation in adults with and without type 1 diabetes.
RESEARCH DESIGN AND METHODS— We studied 16 nondiabetic adults and 16
subjects with type 1 diabetes during euglycemia (blood glucose 4.5 mmol/l) and hypoglycemia
(blood glucose 2.5 mmol/l). Markers of inflammation, thrombosis, and endothelial dysfunction
(soluble P-selectin, interleukin-6, von Willebrand factor [vWF], tissue plasminogen activator
[tPA], high-sensitivity C-reactive protein [hsCRP], and soluble CD40 ligand [sCD40L]) were
measured; platelet-monocyte aggregation and CD40 expression on monocytes were determined
using flow cytometry.
RESULTS— In nondiabetic participants, platelet activation occurred after hypoglycemia,
with increments in platelet-monocyte aggregation and P-selectin (P 0.02). Inflammation was
triggered with CD40 expression increasing maximally at 24 h (3.13  2.3% vs. 2.06  1.0%)
after hypoglycemia (P  0.009). Both sCD40L and hsCRP (P  0.02) increased with a nonsig-
nificant rise in vWF and tPA, indicating a possible endothelial effect. A reduction in sCD40L,
tPA, and P-selectin occurred during euglycemia (P  0.03, P  0.006, and P  0.006, respec-
tively). In type 1 diabetes, both CD40 expression (5.54 4.4% vs. 3.65 1.8%; P 0.006) and
plasma sCD40L concentrations increased during hypoglycemia (peak 3.41 3.2 vs. 2.85 2.8
ng/ml; P 0.03). Platelet-monocyte aggregation also increased significantly at 24 h after hypo-
glycemia (P  0.03). A decline in vWF and P-selectin occurred during euglycemia (P  0.04).
CONCLUSIONS— Acute hypoglycemia may provoke upregulation and release of vasoac-
tive substances in adults with and without type 1 diabetes. This may be a putative mechanism for
hypoglycemia-induced vascular injury.
Diabetes Care 33:1591–1597, 2010
In people with type 1 diabetes the rapidinstitution of strict glycemic controlaggravates microvascular complica-
tions, particularly retinopathy (1). Al-
though attributed to reduced capillary
blood flow causing localized ischemia (1),
greater exposure to hypoglycemia may
have worsened microangiopathy through
its putative effects on local vasculature
(2). In addition, cardiovascular stress as-
sociated with hypoglycemia may precipi-
tate acute macrovascular events in a
diseased circulation. While supported by
anecdotal reports (3), the increase in car-
diovascular mortality in people with type
2 diabetes in the Action to Control Car-
diovascular Risk in Diabetes (ACCORD)
trial (4) (and possibly in the Veterans Af-
fairs Diabetes Trial [5]), in which inten-
sive treatment had tripled the frequency
of severe hypoglycemia, has caused
concern.
Possible mechanisms by which hypo-
glycemia may damage blood vessels in-
clude changes in regional blood flow,
mobilization and activation of neutro-
phils, platelet activation, and enhanced
coagulation and viscosity of the blood
(3,6 – 8). Plasma concentrations of C-
reactive protein, interleukin-6 (IL-6),
and endothelin-1 increase during hypo-
glycemia (9 –11) and may promote vas-
cular disease (12).
Investigation of processes operating
at a cellular level to cause atherosclerosis
has focused on the potential influences
of vascular inflammation, endothelial
dysfunction, coagulation, and platelet ac-
tivation. The present study sought to de-
termine the effects of acute insulin-
induced hypoglycemia on inflammation,
coagulation, and platelet and monocyte
function in adults with and without type 1
diabetes.
RESEARCH DESIGN AND
METHODS— Participants in the
study included 16 nondiabetic adult vol-
unteers with no medical history and 16
healthy adults with type 1 diabetes (Table
1). Those with diabetes had no history of
hypertension or macrovascular disease,
and microvascular disease was excluded.
Screening for retinopathy used digital ret-
inal photography, absence of neuropathy
was confirmed by clinical examination,
and nephropathy was excluded by the ab-
sence of microalbuminuria. Subjects with
a history of impaired awareness of hypo-
glycemia or a previous serious reaction to
hypoglycemia were excluded. None had a
history of head injury, seizure, blackouts,
alcohol or drug abuse and psychiatric ill-
ness, and their only other medication was
the contraceptive pill. Diabetes Control
and Complications Trial–aligned A1C
was measured using high performance
liquid chromatography (nondiabetic ref-
erence range 5.0–6.05%; Bio-Rad Labo-
ratories, Munich, Germany); the mean
SD of the participants with diabetes was
7.91 0.92%. All gave written informed
consent before participation, and the
study was approved by the Local Medical
Research Ethics Committee.
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A modified hyperinsulinemic glucose
clamp (13) was used to maintain blood
glucose at a predetermined level: euglyce-
mia at 4.5 mmol/l and hypoglycemia at
2.5 mmol/l. Each subject underwent two
laboratory sessions, separated by at least 2
weeks (mean 7.2 weeks), of a euglycemic
study and a hypoglycemic study in a ran-
domized, counterbalanced fashion.
The participants with type 1 diabetes
monitored blood glucose intensively dur-
ing the 48 h preceding each study, which
was postponed if any blood glucose value
was3.5 mmol/l or if symptoms sugges-
tive of hypoglycemia were experienced.
After fasting overnight, morning insulin
was withheld. A retrograde-intravenous
cannula for blood-glucose sampling was
inserted into the nondominant hand,
which was heated to arterialize the venous
blood (14). A cannula in the nondomi-
nant antecubital fossa was used to infuse
20% dextrose and soluble insulin (Hu-
man Actrapid; Novo Nordisk, Crawley,
U.K.) at a constant rate of 1.5 mU/kg/min
using a Gemini PCI pump (Alaris Medical
Systems, San Diego, CA). The dextrose
was infused at a variable rate depending
on arterialized blood glucose concentra-
tions, which were measured at 5 min in-
tervals using the glucose oxidase method
(2300 Stat; Yellow Springs Instruments,
Yellow Springs, OH). A third cannula in
the other antecubital fossa was dedicated
to blood sampling for inflammatory
markers.
On each study day, the arterialized
blood glucose was stabilized initially at
4.5 mmol/l for 30 min and either main-
tained at that level (euglycemia) or low-
ered over 20 min to 2.5 mmol/l for 60 min
(hypoglycemia), after which blood glu-
cose was restored to 4.5 mmol/l. Subjects
consumed a standardized meal after each
study. Blood sample time points were:
baseline, during the experimental session
(45 min), during recovery (105 min),
at 6 h, and at 24 h.
Flow cytometry
Whole blood samples were collected
at the predetermined time points using
D-Phenylalanyl-L-prolyl-L-arginine chlo-
romethyl ketone, a selective thrombin in-
hibitor, as an anticoagulant. Samples (100
l) of whole blood were immediately in-
cubated with 10 l of each monoclonal
antibody (AbD Serotec, Kidlington, U.K.)
for 30 min at room temperature, with
subsequent red cell lysis by the addition
of 1 ml of fluorescent-activated cell sorter
(FACS) Lyse solution (Becton Dickinson,
Oxford, U.K.). Flow cytometry using the
FACS Calibur system (Becton Dickinson,
Oxford, U.K.) was performed immedi-
ately after the experimental session to as-
sess platelet-monocyte aggregation
(CD14/CD42a) and CD40 expression on
monocytes (CD14/CD40). Isotype con-
trols were performed in addition to both
mono- and dual-stain for each parameter
assessed at each time point.
Soluble marker assays
Citrated plasma and serum samples
were collected at the predetermined
time points. These were separated imme-
diately and frozen at80°C until analysis
for the soluble markers:
Von Willebrand factor (vWF) (enzyme-
linked immunosorbent assay [ELISA]; co-
efficient of variation [CV] 7.3%), tissue
plasminogen activator (tPA) antigen (Hy-
phen Biomed Zymutest; intra-assay CV
3.5%, inter-assay CV 4.4%), soluble
CD40 ligand (sCD40L) (high sensitivity
ELISA, Bender Medsystems; intra-assay
CV 5.5%, inter-assay CV 7.2%), soluble
P-selectin (ELISA, R&D Systems; intra-
assay CV 5.1%, inter-assay CV 8.8%),
IL-6 (High sensitivity ELISA, R&D Sys-
tems; intra-assay CV 5.9%, inter-assay CV
9.9%), and high sensitivity CRP (DRG Di-
agnostics; DRG Instruments, Marburg,
Germany; intra-assay CV 4.2%, inter-
assay CV 4.1%).
Catecholamine assays
Samples for epinephrine quantification
were collected in EDTA tubes and imme-
diately separated and frozen at 80°C
until analysis by high-performance liquid
chromatography and electrochemical de-
tection (intra-assay CV 1.2%, inter-assay
CV 3.9%).
Hypoglycemia symptom score
The Edinburgh Hypoglycemia Scale (15)
was used to assess the symptoms experi-
enced during each experimental session.
Statistical analyses
Results were analyzed using SPSS version
15.0 for Windows (SPSS, Chicago, IL). A
general linear model (repeated-measures
ANOVA) was used, with order of session
(euglycemia-hypoglycemia or hypoglyce-
mia-euglycemia) as a between-subjects
factor, and condition (euglycemia or hy-
poglycemia) as a within-subjects factor, to
compare hypoglycemia with euglycemia.
Additional analysis using paired t tests
was performed to assess the change in any
given parameter from baseline. A P value
0.05 was considered to be significant.
Results are reported as mean SD unless
otherwise stated.
RESULTS— Hypoglycemia provoked
a symptomatic response in all subjects
with increased scores of autonomic (P 
0.002), neuroglycopenic (P  0.001),
and malaise (P 0.008) symptoms com-
pared with baseline. Comparison of base-
line levels of inflammatory, endothelial
and platelet markers in nondiabetic sub-
jects and subjects with type 1 diabetes
showed a significantly higher concentra-
tion of soluble P-selectin (P  0.01) and
of CD40 expression on monocytes (P 
0.006) in those with diabetes, demon-
strating the chronic inflammatory re-
sponse associated with diabetes.
Blood glucose
Target blood glucose concentrations were
achieved (Fig. 1). In nondiabetic subjects,
blood glucose concentrations were
2.58 0.2 and 4.42 0.5 mmol/l during
hypoglycemia and euglycemia, respec-
tively. In those with type 1 diabetes, blood
glucose concentrations were 2.46  0.22
and 4.53  0.24 mmol/l, respectively.
The blood glucose nadir was similar in
both groups.
Counterregulatory response
Plasma epinephrine increased during hy-
poglycemia in participants with and with-
Table 1—Baseline demographic characteristics
Nondiabetic subjects Subjects with diabetes
n 16 16
Age (years) 28 (26.7–35) 28 (25–37.5)
BMI (kg/m2) 22.86  2.4 26.40  4.0
Male/female 6/10 7/9
Duration of diabetes (years) N/A 10 (4.2–19)
A1C (%) N/A 7.91  0.9
Data are median (interquartile range) and means  SD unless otherwise indicated.
Hypoglycemia and vascular disease
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out type 1 diabetes (P  0.001; Fig. 1).
The epinephrine response occurred only
during hypoglycemia and returned rap-
idly to baseline as anticipated (16).
Platelet activation
Platelet-monocyte aggregation. In non-
diabetic subjects, platelet-monocyte ag-
gregation appeared to rise, from a baseline
level of 0.72  0.8% to 3.09  8.1%
during hypoglycemia, with a peak of
3.49  10.4% at 24 h (Fig. 2). Platelet-
monocyte aggregation remained un-
changed throughout euglycemia. The
difference between conditions, and
from baseline, did not achieve statistical
significance.
In participants with diabetes, there
was a late rise in platelet-monocyte aggre-
gation after hypoglycemia at 24 h com-
pared with baseline (P  0.03).
Soluble P-selectin. Soluble plasma P-
selectin concentrations increased after
hypoglycemia in nondiabetic subjects,
exhibiting a late response at 6 h (P 
0.01) and 24 h (P  0.02; Fig. 2) but
decreasing during euglycemia (P 
0.006).
P-selectin also decreased during eu-
glycemia in the diabetic group (P 0.04),
but did not change during hypoglycemia.
Endothelial markers
tPA. In nondiabetic subjects, plasma tPA
concentrations increased during hypogly-
cemia, with a higher peak tPA concentra-
tion (12.55  16.7 compared with
6.80  7.9 ng/ml) (NS between condi-
tions). Plasma tPA decreased significantly
between baseline and test phase (P 
0.004) and recovery phase (P  0.006),
with a paradoxical rise between baseline
and 24 h (P 0.06) after euglycemia (Ta-
ble 2). However, a diurnal variation in tPA
concentration is recognized to occur,
which may account for the decline ob-
served during euglycemia (17). No signif-
icant differences occurred in the diabetic
group (Table 2).
vWF. A trend toward a difference in
plasma vWF concentrations was observed
between hypoglycemia and euglycemia at
6 h in the nondiabetic subjects (P 0.07)
(Table 2).
Plasma vWF concentrations de-
creased between baseline and test phase
(P 0.02) and recovery phase (P 0.03)
after euglycemia in the participants with
diabetes. No such decrement was ob-
served during hypoglycemia (Table 2).
Inflammation
CD40 expression. CD40 expression on
monocytes increased after hypoglycemia
in nondiabetic subjects, from a baseline of
1.92  2.2% to a maximum of 3.13 
2.3% at 24 h (P  0.009). A significant
difference between hypoglycemia and eu-
glycemia conditions was present at 6 h
(P  0.05) and at 24 h (P  0.04)
(Table 2).
In participants with type 1 diabetes,
monocyte CD40 expression increased
from 3.69 3.4% to 5.54 4.4% during
hypoglycemia (P  0.006), compared
with no change during euglycemia
(3.64  2.0% to 3.65  1.8%, respec-
tively; P  NS). The increment during
Figure 1—A: Blood glucose concentrations during hyperinsulinemic hypoglycemic and euglycemic clamp studies. B: Epinephrine responses to
experimental procedures. i. nondiabetic subjects; ii. subjects with type 1 diabetes.
Wright and Associates
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hypoglycemia had dissipated by the time
of the recovery phase and remained un-
changed thereafter (Table 2).
sCD40L. In nondiabetic subjects,
plasma sCD40L concentrations were
higher during hypoglycemia than during
euglycemia (2.80  3.2 vs. 2.41  2.8
ng/ml), with a trend toward significance
(P  0.09). A significant reduction in
sCD40L concentration occurred during
euglycemia between baseline and recov-
ery phase (P  0.03) (Table 2).
In those with diabetes, a significant
difference was observed between the
baseline levels on each study day: 3.36
2.9 ng/ml on the hypoglycemia day com-
pared with 2.86 2.8 ng/ml on euglyce-
mia day (P 0.03), rendering subsequent
measurements difficult to compare. A sig-
nificant difference was again observed be-
tween the experimental condition levels,
with a level of 3.41  3.2 ng/ml during
hypoglycemia and 2.85 2.8 ng/ml dur-
ing euglycemia (P  0.03) (Table 2).
Changes from baseline did not achieve
significance.
IL-6. IL-6 levels rose in all experi-
ments, maximally at 6 h, irrespective of
condition, with no clear differences iden-
tifiable in either group between the study
conditions (Table 2).
hsCRP. Test phase hsCRP was higher
in all subjects during hypoglycemia
(1.81 1.9 vs. 1.22 1.9 ng/ml in non-
diabetic participants [P  0.02]; 2.72 
3.1 vs. 2.20 2.9 ng/ml in subjects with
diabetes [P ns]) (Table 2). A significant
difference was observed in the baseline
concentrations in the nondiabetic partic-
ipants (P  0.01), frustrating interpreta-
tion of subsequent responses.
CONCLUSIONS— Previous studies
have demonstrated that hypercoagulabil-
ity, platelet and neutrophil activation, C-
reactive protein, IL-6, and Endothelin-1
are upregulated after acute hypoglycemia
(3,6–11), while a euglycemic insulin in-
fusion (for at least 2 h) was shown to re-
duce inflammatory markers, consistent
with an anti-inflammatory effect of insu-
lin (18). The present study sought to
replicate these effects, while investigat-
ing other underlying mechanisms of
vascular disease, and tests were selected
to investigate the effect of acute hypo-
glycemia on important cellular pro-
cesses (platelet activation, endothelial
dysfunction and inflammation) under-
lying the development of acute and
chronic vascular complications in type
1 diabetes.
The present study showed that hypo-
glycemia generated a response in some of
these markers, suggesting that hypoglyce-
mia-induced metabolic stress may have
adverse pathophysiological consequences
while the euglycemic insulin infusion
caused a potentially beneficial decrement
in some parameters. However, the magni-
tude of most observed changes was small,
and not all markers changed significantly.
The present study confirmed that
platelet activation is promoted by hypo-
glycemia (8), with increments both in
platelet-monocyte aggregation and solu-
ble P-selectin. Conversely, P-selectin de-
creased during euglycemia. Endothelial
function, using vWF and tPA Ag as surro-
gate markers, may have been disrupted,
as shown by the increase in vWF after
hypoglycemia in nondiabetic volunteers,
but this change was not replicated in
those with diabetes. However, a reduc-
Figure 2—Platelet activation in response to experimental hypoglycemia and euglycemia. A: Platelet-monocyte aggregation. B: Soluble P-selectin,
i. Nondiabetic subjects, ii. Subjects with type 1 diabetes.
Hypoglycemia and vascular disease
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tion in vWF occurred after euglycemia in
diabetic participants, which should con-
fer vascular benefit. tPA Ag also appeared
to increase in nondiabetic subjects during
hypoglycemia, while declining during eu-
glycemia, whereas no significant changes
occurred in the diabetic group. Soluble
markers of inflammation, sCD40L and
hsCRP, were higher during hypoglyce-
mia, with an elevation of hsCRP being ob-
served in all subjects. Unfortunately,
baseline differences in hsCRP in nondia-
betic subjects, and in sCD40L in the dia-
betic subjects, frustrated interpretation of
subsequent responses. sCD40L was ap-
parently reduced during euglycemia in
nondiabetic participants. Surprisingly,
IL-6 increased in all experiments regard-
less of glycemic status, with a maximal
response at 6 h. This response is inexpli-
cable, and contrasts with a previous re-
port (10). Monocyte CD40 expression
also increased, suggesting promotion of
the interaction of the CD40-CD40 ligand
dyad (from the tumor necrosis factor re-
ceptor family), thus affecting another
process in the pathway leading to athero-
sclerotic plaque rupture (19,20). This
change occurred much earlier in the dia-
betic than the nondiabetic subjects, in
whom the response was delayed, pro-
longed, and still present at 24 h. The per-
sistence of these vascular changes for 24 h
after the hypoglycemic stimulus, or their
later emergence, suggests that the period
of risk after hypoglycemia may be present
long after blood glucose recovery.
For some markers, a positive trend
after hypoglycemia was evident, without
achieving statistical significance, or the
only measurable difference between con-
ditions was a beneficial effect associated
with euglycemia. The sample size may
have been insufficient to achieve signifi-
cance, particularly as the magnitude of re-
sponses was small. It was not feasible to
study a larger number of subjects using a
procedure that is labor-intensive and
costly. In a previous study, larger incre-
ments in inflammatory markers were ob-
served during an insulin tolerance test,
where hypoglycemia of39 mg/dl (2.2
mmol/l) was induced (21). The more
rapid reduction to a lower blood glucose
causing a greater hypoglycemic stimulus
may have heightened the magnitude of
the responses, compared with the more
modest changes that occurred during a
controlled glucose clamp (blood glucose
2.5 mmol/l [45 mg/dl]), as observed in
the present study. A further limitation
of the present study was the need to ex-
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amine the experimental conditions on two
separate days in a counterbalanced fash-
ion. Because the baseline levels of many
inflammatory markers can differ on sepa-
rate days, as was observed with sCD40L
and hsCRP, this biological variability hin-
ders the interpretation and comparison of
subsequent results. However, the present
study design was necessary to allow com-
parison of the euglycemia and hypoglyce-
mia conditions in individual subjects, as
both time and insulin infusion per se may
exert effects on biomarker levels. This
study design cannot control for other day-
to-day factors that could influence base-
line levels of inflammatory markers.
However, the effects of hypoglycemia
could be evaluated, as each participant
acted as their own control. This produces
less variability than a comparison of re-
sults among individuals, as more inter-
individual variation in inflammatory
marker levels is present than intra-
individual variation. In addition, it was
possible to analyze each study separately,
by examining changes in parameters from
baseline on that particular day, enabling
the detection of significant effects exerted
by hypoglycemia compared with euglyce-
mia. Baseline levels of all markers (except
IL-6) were higher in the diabetic group
(significant for P-selectin and CD40 ex-
pression). This could affect the magni-
tude of response induced by the
experimental procedures. However, an
analysis of the percentage change from
baseline was consistent with the trends
identified in the absolute results (shown
as in the online appendix available at
http://care.diabetesjournals.org/cgi/
content/full/dc10-0013/DC1).
As anticipated, epinephrine secre-
tion was stimulated by hypoglycemia. It
is likely that hormonal changes underlie
the activation and upregulation of the
vascular biomarkers. Catecholamines
promote platelet activation (22), while
adrenoceptor blockade attenuates these
effects (23,24). The participants with
type 1 diabetes exhibited attenuated
plasma epinephrine responses to hypo-
glycemia compared with the nondia-
betic subjects, who were naïve to such a
hypoglycemic stimulus, this being con-
sistent with the recognized decline in
the magnitude of counterregulatory
hormonal responses with increasing
duration of type 1 diabetes (25). This
attenuated epinephrine response may
explain the lower responses of vascular
biomarkers to hypoglycemia.
In summary, the effects of hypogly-
cemia on several vascular biomarkers
that are implicated in the pathogenesis
of vascular disease, would support the
premise that acute hypoglycemia may
be detrimental to an already diseased
vasculature (2). Euglycemia may have a
protective, anti-inflammatory effect. In
the present study, the participants had
no overt vascular disease and were un-
likely to develop any demonstrable ef-
fects from a short period of exposure to
hypoglycemia. However, in people with
diabetes of long duration, who are likely
to have underlying vascular disease,
these responses may not be benign. The
release of potent vasoactive substances
could potentially aggravate chronic vas-
culopathy, and contribute to the precip-
itation of acute macrovascular events.
This may aggravate established diabetic
micro- and macrovascular disease in
those who are exposed to recurrent
hypoglycemia.
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